Recent Therapeutic Strategies for Psoriatic Arthritis: Optimal Management for Personalized Patient Care

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive of the live session from the 2021 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2021 – August 1, 2022
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AbbVie and Novartis Pharmaceuticals Corporation

Description:
Psoriatic arthritis is a debilitating disease that may affect up to 1 million adults in the United States, affecting men and women equally. Psoriatic arthritis is a progressive, inflammatory disease that is associated with a number of dermatologic and musculoskeletal manifestations. Patients can experience extreme pain and joint damage that may affect their quality of life, physical function, and ability to work. Symptoms include fatigue, joint inflammation, and potentially progressive joint damage.Diagnosing psoriatic arthritis can be very complex and the standard diagnostic measures are based on history, a physical exam and x-ray features, so establishing the presence of characteristic signs and symptoms associated in both the skin and joints, and by ruling out more common inflammatory arthritis, can be very helpful. The most commonly accepted diagnostic criterion is the CAPSER classification. The diagnosis of psoriatic arthritis can sometimes be delayed or missed by primary care providers and other healthcare professionals. With recent updates to the guidelines, there have been updates and advances in digital imaging tools and screening options that have improved the chances of catching psoriatic arthritis early, which allows for better treatment goals to be achieved.

The past few years have seen a number of treatments introduced for psoriatic arthritis. Along with symptomatic treatments, such as nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and local corticosteroid injections into joints, there are also the oral small molecules (OSMs) for treatment. The Tumor Necrosis Factor (TNF) inhibitors have been available for nearly 20 years and continue to be a viable option for patients. More recently key cytokines in the psoriatic disease pathophysiology have been introduced and they include Janus kinases and signal transducers and activators of transcription (JAK-STATs) as well as are the interleukin (IL)-12, IL-17, IL-22 and IL-23 pathway inhibitors. These newer biologic treatments target some of these key cytokines to treat psoriatic disease. Clinicians need to be able to incorporate these new approaches into treatment paradigms, considering both safety and efficacy, by being educated with appropriate management strategies that will guide treatment decisions for patients with psoriatic arthritis.

Upon completion of this activity, participants will be able to:

  • Analyze clinical tools for assessing joint symptoms and diagnosing psoriatic arthritis (PsA)

  • Discuss the current guidelines and evidence to make appropriate decisions for patients who require systemic targeted therapies in PsA

  • Explore new and emerging targeted therapies for PsA based on mechanisms of action, efficacy and safety data, and comparative effectiveness

  • Assess short and long-term strategies that account for risk management in patients with PsA

  • Identify multidisciplinary approaches for effective PsA treatment and management to address common comorbidities, adherence, and adverse events

     

Faculty: Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic

Disclosure:

Dr. Calabrese serves as a consultant for AbbVie, Bristol Myers Squibb, Genentech, Janssen, Lilly, Novartis and UCB. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no financial relationships with ineligible companies to disclose.
Jeremy Williams has no financial relationships with ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial relationships with ineligible companies to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AbbVie and Novartis Pharmaceuticals Corporation

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue